Centessa Pharmaceuticals (CNTA) Non-Current Assets (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Non-Current Assets data on file, last reported at $293.1 million in Q1 2026.

• Quarterly Non-Current Assets rose 62.71% year-over-year to $293.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $945.1 million (up 209.65% YoY) and the FY2025 annual result came in at $319.6 million, up 691.35% from the prior year.
• Non-Current Assets fell to $293.1 million in Q1 2026 per CNTA's latest filing, from $319.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $319.6 million in Q4 2025 and bottomed at $993000.0 in Q1 2022.
• The 5-year median for Non-Current Assets is $43.3 million (2024), against an average of $85.7 million.
• The widest annual swing landed in 2023, when Non-Current Assets surged 2637.15%; it then decreased 10.55% in 2024.
• Tracing CNTA's Non-Current Assets over 5 years: stood at $6.6 million in 2022, then jumped by 588.32% to $45.2 million in 2023, then dropped by 10.55% to $40.4 million in 2024, then surged by 691.35% to $319.6 million in 2025, then slipped by 8.3% to $293.1 million in 2026.
• Per Business Quant, the three latest CNTA Non-Current Assets figures stand at $293.1 million (Q1 2026), $319.6 million (Q4 2025), and $140.6 million (Q3 2025).

Peer Comparison